Article
Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs
2023-10-21
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> The five-year survival for non-metastatic non-small cell lung cancer (NSCLC) patients undergoing curative surgery remains poor at ∼50% that is due to locoregional and/or distant metastatic recurrences. Patient-derived tumor organoids (PDTOs) have high potential as clinically relevant high-throughput drug testing platforms to personalize and improve treatment of NSCLC patient...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b4485d98-ecdf-5ff1-b1a7-ac517321eb9a
- DOI
- 10.1101/2023.10.18.562944
